{# Audit 04/10/2026 : « autre » n'est pas un code de langue ; SPHAERO n'est pas l'éditeur des documents qu'elle héberge ou référence. #} {# citation_pdf_url doit mener à un PDF : un lien vers une page DOI est pénalisé par Google Scholar (avant : tout lien externe). #}
Accès ouvert · CC BY

Effect of a combination of Xuebijing and thymosin α1 on patients with severe pneumonia complicated with sepsis, and its influence on serum inflammatory factors

Article scientifique 2022 Anglais

Résumé

Purpose: To investigate the influence of a combination of Xuebijing and thymosin α1 on acute and septic bronchopneumonia (ASB) patients, and the effect of the treatment on inflammation. Methods: Eighty-one (81) ASB patients admitted to Tianjin Medical University General Hospital, Tianjin China from January 2015 to July 2019 were enrolled in the study. The patients were assigned to control group (n = 41) and a study group (n = 40). The control patients were treated with Xuebijing injection, i.v., while the study group received a combination of Xuebijing injection and thymosin α1 via the subcutaneous route. Patients’ body temperature, heartbeat, white blood cell count, as well as other parameters, including blood gas indices, serum concentrations of IL-6, TNF-α and C-reactive protein (CRP), as well as well as blood gas indices were determined by enzyme-linked immunosorbent assay (ELISA). Bacterial clearance and therapeutic effectiveness were evaluated pre- and post-treatment. Results: Post-therapy basal temperature, breathing, heartbeat, number of white blood cells and other indices decreased in study patients, relative to control (p < 0.05). Moreover, the levels of hydrogen ion concentration (pH) and arterial carbon dioxide partial pressure (PaCO2) were significantly lower in study group than in control group (p < 0.05). Patients in the study group had lower serum levels of IL-6, TNF-α and CRP, when compared to control group, while bacterial load was significantly reduced in study subjects, relative to controls (p < 0.05). Conclusion: Combined use of thymosin α1 and Xuebijing is significantly effective in the management of patients suffering from ASB. The combination therapy also improves the hemorheological status of patients. Thus, it is a potential therapeutic strategy for ASB. Keywords: Acute bronchopneumonia; Xuebijing; Thymosin α1; Septicemia; Inflammation

Citer ce document

Li, Y., Wang, S., Zhang, J., & Cao, J. (2022). Effect of a combination of Xuebijing and thymosin α1 on patients with severe pneumonia complicated with sepsis, and its influence on serum inflammatory factors. Tropical Journal of Pharmaceutical Research. https://doi.org/10.4314/tjpr.v21i7.22

Exporter : BibTeX · RIS (Zotero, Mendeley, EndNote)

Accès au document

Texte intégral en lecture en ligne, réservé aux abonnés SPHAERO et aux membres de l'institution. Se connecter

Voir l'article sur le site de la revue

Licence et provenance

Licence : CC BY

Notice moissonnée depuis OpenAlex le 09/09/2026. Le document reste hébergé par sa source.
Voir le document à la source →

Statistiques

Consultations : 2

Téléchargements : 0